Details for New Drug Application (NDA): 021856

✉ Email this page to a colleague

NDA 021856 describes ULORIC, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ULORIC profile page.

The generic ingredient in ULORIC is febuxostat. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the febuxostat profile page.

Summary for 021856

Tradename:	ULORIC
Applicant:	Takeda Pharms Usa
Ingredient:	febuxostat
Patents:	3

Pharmacology for NDA: 021856

Mechanism of Action	Xanthine Oxidase Inhibitors

Medical Subject Heading (MeSH) Categories for 021856

Gout Suppressants

Suppliers and Packaging for NDA: 021856

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ULORIC	febuxostat	TABLET;ORAL	021856	NDA	Takeda Pharmaceuticals America, Inc.	64764-677	64764-677-11	10 BLISTER PACK in 1 CARTON (64764-677-11) / 10 TABLET in 1 BLISTER PACK
ULORIC	febuxostat	TABLET;ORAL	021856	NDA	Takeda Pharmaceuticals America, Inc.	64764-677	64764-677-13	100 TABLET in 1 BOTTLE (64764-677-13)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	40MG
Approval Date:	Feb 13, 2009	TE:	AB	RLD:	Yes
Patent:	7,361,676	Patent Expiration:	Mar 8, 2024	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	8,372,872	Patent Expiration:	Sep 8, 2031	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
Patent:	9,107,912	Patent Expiration:	Sep 8, 2031	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE

Expired US Patents for NDA 021856

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009	5,614,520	⤷ Subscribe
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009	5,614,520	⤷ Subscribe
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009	6,225,474	⤷ Subscribe
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009	7,361,676	⤷ Subscribe
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009	6,225,474	⤷ Subscribe
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009	7,361,676	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.